The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.

HPAPI manufacturing requires the highest safety and containment standards. With geopolitical tensions threatening critical ...

The latest in a trend of companies stepping back from cell and gene therapies amid regulatory uncertainty and manufacturing ...

Nearly two dozen antibody drug conjugates (ADCs) have now been approved worldwide and revenues were already well into the ...

ICH gives CGT developers a regulatory framework that finally matches the speed and flexibility their groundbreaking therapies ...

Health Canada has granted conditional approval for Gilead Sciences’ Lyvdelzi for PBC patients who have difficulty with ...

The results strengthen Jiangsu Hengrui’s dominance in the Chinese HCC market, showing potential for camrelizumab and ...

Ventus has entered a multi-year partnership with Roche’s Genentech for the discovery and optimisation of new small-molecule ...

At AAO 2025, EyePoint Pharmaceuticals presented updates on its investigational therapy EYP-1901 (vorolanib) for DME and wAMD.

Merck KGaA could now have a head start in the race to market Precem-TcT, which could become the first widely approved ADC in ...

The US FDA has granted approval for Roche's Gazyva/ Gazyvaro to treat adult patients with active LN who are on standard ...

These Phase III results could enhance uptake of Eli Lilly's Verzenio alongside ET in the adjuvant breast cancer setting, if ...